H.C. Wainwright lowered the firm’s price target on Unicycive Therapeutics to $2.50 from $4.50 and keeps a Buy rating on the shares post the Q2 report. The analyst cites equity dilution for the target cut.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Therapeutics reports Q2 EPS (15c), consensus (19c)
- Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
- Is UNCY a Buy, Before Earnings?
- Unicycive Therapeutics management to meet virtually with Piper Sandler
- Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)